Ipsen Press Releases | Latest News & Updates_emc易倍官网入口

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 246 Press Releases

Show

Sort

19 May 2026

19 May 2026

Download Ipsen announces late-breaking data from first head-to-head study comparing Dysport? and Botox? in adults with upper limb spasticity

Ipsen announces late-breaking data from first head-to-head study comparing Dysport? and Botox? in adults with upper limb spasticity

16 May 2026

16 May 2026

Download Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

15 May 2026

15 May 2026

Download Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement in patients with PBC

Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement in patients with PBC

14 May 2026

14 May 2026

Download Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI?, at the SCALE Symposium

Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI?, at the SCALE Symposium

23 April 2026

23 April 2026

Download Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance

Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance

Ipsen Q1 2026 Press Release (251.12 KB)

Ipsen Q1 2026 Highlights (404.22 KB)

Ipsen Q1 2026 Investor presentation (1.05 MB)

Your dedicated contacts

Sally Bain

Head of Global Media Relations

+1 857 320 0517

sally.bain@ipsen.com

Anne Liontas

France Media Relations

+33 7 67 34 72 96

anne.liontas.ext@ipsen.com

Stay updated

Register to receive our latest news

2026-05-21 5:50:53